Precision BioSciencesDTIL
About: Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Employees: 108
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
9% more funds holding
Funds holding: 47 [Q2] → 51 (+4) [Q3]
0.2% more ownership
Funds ownership: 45.77% [Q2] → 45.97% (+0.2%) [Q3]
3% less capital invested
Capital invested by funds: $30.9M [Q2] → $29.8M (-$1.07M) [Q3]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for DTIL.